Therapeutic
Applications of Interleukin 24 (IL24): A Review
Muhammad
Imran Amirzada1 and Jian Jin1,2*
1School of Biotechnology, Jiangnan University,
2School of Medicine and Pharmaceutics, Jiangnan
University, Wuxi, Jiangsu, 214122, PR China
*For correspondence:
Email:
algin@pharmacy.ankara.edu.tr or
evrenalgin@yahoo.com Tel: +90-532-382
56 86
Received: 9 December 2011 Revised
accepted: 23 October 2012
Tropical
Journal of Pharmaceutical Research, December 2012;
11(6):
1023-1027
http://dx.doi.org/10.4314/tjpr.v11i6.20
Abstract
Fisher’s
group identified melanoma differentiation-associated
protein-7 (MDA-7) upon discovery of cell surface
receptor MDA-7 renamed Interleukin 24 (IL24).It has
three N-glycosylation sites. IL24 signals through
receptors. Binding of IL24 to receptors leads to the
activation of STAT-3 and STAT-1. IL 24 induces the
secretion of high level of Interferon Gamma
(IFN-γ) ,IL6
and tumor necrosis factor alpha (TNF-α)
and low levels of IL1,IL12 and granulocyte macrophage
colony stimulating factor (GM-CSF) from human peripheral
blood mononuclear cells(PBMC). IL24 has growth
suppressive properties in a wide variety of human cancer
cell lines without inducing harmful effects in normal
cells. This review is focused on the role of IL 24 on
tumor cell biology and its potential therapeutic
applications.
Keywords: Melanoma differentiation,
Protein, Therapeutics, Interleukin, N-glycosylation,
Cancer
